Jefferies Group’s Larimar Therapeutics LRMR Stock Holding History

Jefferies Group’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,658	Closed	-$373K	–	2304
2016 Q1	$373K	Sell	4,658 -167	-3%	-$13.2K	﹤0.01%	1582
2015 Q4	$364K	Buy	4,825 +1,883	+64%	+$302K	﹤0.01%	1698
2015 Q3	$1.13M	Buy	+2,942	New	+$1.33M	0.01%	1156

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Jefferies Group's LRMR Position: Q3 2019 in Review

Jefferies Group sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 2,220 shares — an estimated $32K sold.

Jefferies Group first reported a position in LRMR in Q2 2015 and held it in 6 quarters. The position peaked at $758K in Q3 2015. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

Jefferies Group reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
Jefferies Group sold 2,220 Larimar Therapeutics shares in Q3 2019, an estimated $32K.
Jefferies Group first reported a position in Larimar Therapeutics in Q2 2015 and held it in 6 quarters.
Jefferies Group's Larimar Therapeutics position peaked at $758K in Q3 2015.
51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.